[Corrections] Correction to Lancet Diabetes Endocrinol 2019; published online March 1. DOI:10.1016/ S2213-8587(19)30066-X

Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2019; published online March 1. DOI:10.1016/S2213-8587(19)30066-X—In figure 3C of this Article, the height of both bars was incorrect and should have matched the percentages given as datapoints. This change does not affect the written interpretation. This correction has been made to the online version as of March 11, and will be made to the printed Article.

Bekijk het originele bericht